Liver study of cancer drug amcenestrant halted early
NCT ID NCT05126329
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study looked at how the drug amcenestrant is processed in the body of women aged 40-75 with mild or moderate liver problems, compared to women with healthy livers. The goal was to understand dosing and safety. However, the trial was terminated before completion, so no useful results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amcenestrant
- What could go wrong
- The trial was terminated early, so no data were collected. It is unclear if amcenestrant is safe or effective in people with liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number :2760001
Kiel, 24105, Germany
-
Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational site number :4100002
Cheongju-si, 28644, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.